Iridex Cyclo G6 User manual

IRIDEX Cyclo G6™Laser System
Operator Manual

IRIDEX Cyclo G6™Laser System Operator Manual
66294-EN Rev D 2018
© 2018 by IRIDEX Corporation. All rights reserved.
IRIDEX, the IRIDEX logo, IRIS Medical, MicroPulse, and SmartKey are registered trademarks; CW-Pulse,
FiberCheck, FlexFiber, G-Probe, Cyclo G6, LongPulse, MilliPulse, PowerStep, are trademarks of IRIDEX
Corporation. All other trademarks are the property of their respective holders.

66294-EN Rev D
iii
Contents
1Introduction.............................................................................................................1
Compatible Delivery Devices.............................................................................................1
Pulse Types.........................................................................................................................2
References...........................................................................................................................4
Indication for Use ...............................................................................................................5
References...........................................................................................................................7
Warnings and Cautions.......................................................................................................8
IRIDEX Corporation Contact Information .........................................................................9
2Setup.......................................................................................................................10
Unpacking the System ......................................................................................................10
Choosing a Location.........................................................................................................11
Connecting the Components.............................................................................................11
3Operation...............................................................................................................13
Front Panel Controls.........................................................................................................13
Powering the Laser On and Off ........................................................................................13
Treating Patients...............................................................................................................14
Using the Laser System ....................................................................................................15
4Troubleshooting ....................................................................................................22
General Problems..............................................................................................................22
Error Messages .................................................................................................................23
5Maintenance..........................................................................................................25
Inspecting and Cleaning the Laser....................................................................................25
Inspecting and Cleaning the Footswitch...........................................................................25
Verifying the Power Calibration.......................................................................................25
6Safety and Compliance.........................................................................................28
Protection for the Physician..............................................................................................28
Protection for All Treatment Room Personnel..................................................................28
Safety Compliance............................................................................................................30
Labels................................................................................................................................31
Symbols (As Applicable)..................................................................................................33
Specifications....................................................................................................................35
7Wireless Footswitch and EMC ............................................................................36
Setting Up the Wireless Footswitch..................................................................................36
Testing the Batteries .........................................................................................................36
EMC Safety Information...................................................................................................37
EMC Requirements for Console and Accessories ............................................................38

iv
66294-EN Rev D
Contents

66294-EN Rev D
Introduction 1
1
Introduction
The IRIDEX Cyclo G6™ Laser System is a semiconductor diode laser that delivers true continuous wave
infrared (810 nm) laser light for ophthalmic applications. Improper use of the laser system can result in adverse
effects. Follow the instructions for use described in this operator manual.
Compatible Delivery Devices
These IRIDEX Familiesof ProbeDelivery Devices are compatible with the Cyclo G6 laser system:
•MicroPulse® Family
–MicroPulse P3: A single-use, RFID, fiber-optic handheld delivery device that when used with the
Cyclo G6, transmits 810 nm MicroPulse laser energy transsclerally to the ciliary processes for the treatment
of glaucoma. The fiber-optic tip of the MicroPulse P3 is 600-μm diameters and protrudes 0.4 mm from the
handpiece which allows accurate positioning of the fiber-optic tip at 3 mm posterior to the limbus.
–The MicroPulse Family may also include additional probes.
•G-Probe™Family
–G-Probe: A single-use, RFID, fiber-optic handheld delivery device that when used with the Cyclo G6,
transmits continuous-wave infrared laser transsclerally to the ciliary processes for the treatment of
glaucoma. The fiber-optic tip of the G-Probe is 600-μm diameter and protrudes 0.7 mm from the
handpiece which allows accurate positioning of the fiber-optic tip at 1.2mm posterior to the limbus.
–G-Probe™ Illuminate: Identical to the G-Probe with the addition of transillumination.
Transillumination aids the physician in identifying the location of the ciliary processes.
–The G-Probe Family may also include additional probes.
NOTE: Refer to the appropriate delivery device “Instructions For Use” for indications for use,
contraindications, precautions, and adverse effects information.
Illumination Control and Light Regulation
The IRIDEX Cyclo G6 Laser System includes a white light illumination source for augmenting visualization of
target tissue during treatment. Compatible delivery devices, such as G-Probe Illuminate, contain illumination
fibers for carrying white light from the console to the distal tip of the device. The light source is a white (broad
spectrum) LED that is driven from 0 –5 mW; the power level (and therefore the amount of illumination) is
adjustable by the user via the touch screen interface on the console and remote control. Power to the white LED
is normally OFF; power ON is managed automatically by the console when a compatible connector is inserted
into the light source orifice. An optical microswitch in the light source orifice detects proximity of a compatible
connector and triggers the ON/OFF function of the illumination source.

2 IRIDEX Cyclo G6™Laser System Operator Manual
66294-EN Rev D
Pulse Types
Two pulse types are available: CW-Pulse™ and MicroPulse® mode.
CW-Pulse™
Laser emission is continuous during the entire timed exposure.
MicroPulse®
MicroPulse (P) is a laser delivery consisting of a group of microsecond bursts.
Duty Cycle%= P Duration × 100
P +
Duration P
Interval
P
Interval MicroPulse
Pulse Envelope
Duration
P
Duration
Pulse Envelope
Interval Time (ms)
Interval
Pulse Duration
Time (ms)
Power (W)
Power (W)

66294-EN Rev D
Introduction 3
MicroPulse® is typically used to administer subvisible threshold laser treatments to macular and perimacular
targets. When used here, the terms “subvisible”, “subvisible threshold” or “subthreshold” denote that the desired
endpoint is one in which treated tissue offers no ophthalmoscopically observable laser effects. Nevertheless,
studies using 810 nm lasers have confirmed that subvisible laser treatment strategies can be clinically effective
while inducing no changes discernible by slit lamp observation, fluorescein angiography (FA), fundus
autofluorescence (FAF), or at any time postoperatively.1,2
Tissues receiving subvisible MicroPulse® laser treatment show no such changes because:
•MicroPulse® laser delivery is being used instead of CW, and
•The total laser energy of such doses is only a percentage (often chosen by clinicians to be 20-70%) of that
energy needed to produce a visible endpoint.
Energy (J) is equal to [Laser Power (W)] × [Exposure Duration(s)] × [Duty Factor (%/100)]. Duty Factor is often
5% to 15% when using MicroPulse® mode, and is 100% when using CW mode. Clinicians have reported various
strategies to adjust these parameters relative to suprathreshold burns in order to achieve clinically effective
subvisible endpoints.1-4
Additional parameters to consider in any laser treatment protocol, and particularly during MicroPulse®, is
spacing between laser treatment spots, and the total number of treatment spots administered. Due to the limited
thermal spread of MicroPulse® exposures, subvisible treatments often call for the administration of a greater
number of treatment spots with denser spacing than that used for threshold laser grid treatments.4

4 IRIDEX Cyclo G6™Laser System Operator Manual
66294-EN Rev D
References
1. Sasoh M, Smiddy W: Diode Laser Endophotocoagulation. Retina 1995;15(5):388-393.
2. Akduman, L, Olk, RJ: Diode Laser (810 Nm) Versus Argon Green (514 Nm) Modified Grid Photocoagulation
for Diffuse Diabetic Macular Edema. Ophthalmology 1997;104(9):1433-41.
3. Ulbig MW, McHugh DA, Hamilton AM: Diode Laser Photocoagulation for Diabetic Macular Oedema.
Br J Ophthalmol 1995;79(4):318-21.
4. Luttrull JK, Sramek C, Palanker D, Spink CJ, Musch DC: Long-Term Safety, High-Resolution Imaging, and
Tissue Temperature Modeling of Subvisible Diode Micropulse Photocoagulation for Retinovascular Macular
Edema. Retina 2012;32(2):375-86.
5. Vujosevic S, Bottega E, Casciano M, Pilotto E, Convento E, Midena E: Microperimetry and Fundus
Autofluorescence in Diabetic Macular Edema: Subthreshold Micropulse Diode Laser Versus Modified Early
Treatment Diabetic Retinopathy Study Laser Photocoagulation. Retina 2010;30(6):908-916.
6. Agarwal HC, Poovali S, Sihota R, Dada T: Comparative Evaluation of Diode Laser Trabeculoplasty Vs.
Frequency Doubled Nd : YagLaser Trabeculoplastyin PrimaryOpenAngleGlaucoma.Eye2006;20(12):1352-6.
7. Chung PY, Schuman JS, Netland PA, Lloyd-Muhammad RA, Jacobs DS: Five-Year Results of a Randomized,
Prospective, Clinical Trial of Diode Vs Argon Laser Trabeculoplasty for Open-Angle Glaucoma.
Am J Ophthalmol 1998;126(2):185-90.
8. Panarelli, JF, Banitt, MR, Sidoti, PA: Transscleral Diode Laser Cyclophotocoagulation after Baerveldt
Glaucoma Implant Surgery. J Glaucoma 2012.
9. Wilensky, JT, Kammer, J: Long-Term Visual Outcome of Transscleral Laser Cyclotherapy in Eyes with
Ambulatory Vision. Ophthalmology 2004;111(7):1389-92.
10. Schlote T, Derse M, Rassmann K, Nicaeus T, Dietz K, Thiel HJ: Efficacy and Safety of Contact Transscleral
Diode Laser Cyclophotocoagulation for Advanced Glaucoma. J Glaucoma 2001;10(4):294-301.
11. Haller JA, Blair N, de Juan E Jr, De Bustros S, Goldberg MF, Muldoon T, Packo K, Resnick K, Rosen R,
Shapiro M, Smiddy W, Walsh J: Transscleral Diode Laser Retinopexy in Retinal Detachment Surgery: Results
of a Multicenter Trial. Retina 1998;18(5):399-404.
12. Kapran Z, Uyar OM, Bilgin BA, Kaya V, Cilsim S, Eltutar K: Diode Laser Transscleral Retinopexy in
Rhegmatogenous Retinal Detachment Surgery. Eur J Ophthalmol 2001;11(4):356-60.
13. Odergren, A, Algvere, PV, Seregard, S, Kvanta, A: A Prospective Randomised Study on Low-Dose
Transpupillary Thermotherapy Versus Photodynamic Therapy for Neovascular Age-Related Macular
Degeneration. Br J Ophthalmol 2008;92(6):757-61.
14. Sharma, T, Krishnan, T, Gopal, L, Nagpal, A, Khetan, V, Rishi, P: Transpupillary Thermotherapy for
Circumscribed Choroidal Hemangioma: Clinical Profile and Treatment Outcome. Ophthalmic Surg Lasers
Imaging 2011;42(5):360-8.
15. Shields CL, Shields JA, Perez N,SinghAD, Cater J: PrimaryTranspupillaryThermotherapyforSmallChoroidal
Melanoma in 256 Consecutive Cases: Outcomes and Limitations. Ophthalmology 2002;109(2):225-34.
16. Banach, MJ, Berinstein, DM: Laser Therapy for Retinopathy of Prematurity. Curr Opin Ophthalmol
2001;12(3):164-70.
17. Axer-Siegel, R, Snir, M, Cotlear, D, Maayan, A, Frilling, R, Rosenbaltt, I, Weinberger, D, Kremer, I, Sirota, L:
Diode Laser Treatment of Posterior Retinopathy of Prematurity. Br J Ophthalmol 2000;84(12):1383-6.
18. Manayath, GJ, Narendran, V, Arora, S, Morris, RJ, Saravanan, VR, Shah, PK: Graded Subthreshold
Transpupillary Thermotherapy for Chronic Central Serous Chorioretinopathy. Ophthalmic Surg Lasers
Imaging 2012;43(4):284-90.
19. Chen SN, Hwang JF, Tseng LF, Lin CJ: Subthreshold Diode Micropulse Photocoagulation for the Treatment
of Chronic Central Serous Chorioretinopathy with Juxtafoveal Leakage. Ophthalmology2008;115(12):2229-34.
20. LanzettaP,Furlan F, MorganteL,Veritti D, Bandello F: NonvisibleSubthresholdMicropulse Diode Laser(810
Nm) Treatment of Central Serous Chorioretinopathy. A Pilot Study. Eur J Ophthalmol 2008;18(6):934-40.
21. Koss MJ, Beger I, Koch FH: Subthreshold Diode Laser Micropulse Photocoagulation Versus Intravitreal
Injectionsof Bevacizumab in the Treatment of Central Serous Chorioretinopathy. Eye (Lond) 2012;26(2):307-14.
22. Parodi MB, Spasse S, Iacono P, Di Stefano G, Canziani T, Ravalico G: Subthreshold Grid Laser Treatment of
Macular Edema Secondary to Branch Retinal Vein Occlusion with Micropulse Infrared (810 Nanometer) Diode
Laser. Ophthalmology 2006;113(12):2237-42.

66294-EN Rev D
Introduction 5
Indication for Use
This section provides information on the use of the laser in clinical specialties. Information is provided by
specialty and includes procedural recommendations along with specific indications and contraindications. This
information is not intended to be all-inclusive and is not intended to replace surgeon training or experience. The
regulatory information provided is applicable only in the United States. If the laser is used for indications not
included herein, the user will be subject to 21 CFR Part 812, the Food and Drug Administration’s Investigational
Device Exemption (IDE) regulations. For information regarding the regulatory status of indications other than
those listed in this manual, contact IRIDEX Regulatory Affairs.
IRIDEX does not make recommendations regarding the practice of medicine. References in literature are
provided as a guide. Individual treatment should be based on clinical training, clinical observation of laser tissue
interaction, and appropriate clinical endpoints.
Indication for Use
The Family of IRIDEX IQ Laser Systems (IQ 532 [532nm], IQ 577 [577nm], IQ 630-670 [630nm-670nm],
IQ 810 [810nm] [IRIDEX Cyclo G6 Laser System]) and the hand pieces, delivery devices & accessories that are
used with them to deliver laser energy in either CW-pulse, MicroPulse® or LongPulse™ mode. Intended for soft
and fibrous tissue, including osseous tissue incision, excision, coagulation, vaporization, ablation and vessel
hemostasis in the medical specialties of, dermatology, ear, nose and throat (ENT)/ otolaryngology, and
ophthalmology as follows:
810nm (The IRIDEX Cyclo G6 Laser System)
Ophthalmology:
The IRIDEX Cyclo G6™ Laser System and Probe Delivery Devices (G-Probe, G-Probe Illuminate, &
MicroPulse® P3) are used to deliver laser energy in either CW-Pulse (CW) or MicroPulse (μP) treatment mode
and indicated for the treatment of Glaucoma:
DELIVERY
DEVICE
Condition
(Indicated for)
Treatment
(Intended Use)
CW/μP
MicroPulse® P3
Device
For the treatment of Glaucoma
including:
•Primary Open-Angle
•Closed-Angle
•Refractory
Transscleral cyclophotocoagulation
(TSCPC) of the ciliary processes
μP
G-Probe
&
G-Probe Illuminate
For the treatment of Glaucoma
including:
•Primary Open-Angle
•Closed-Angle
•Refractory
Transscleral cyclophotocoagulation
(TSCPC) of the ciliary processes
CW
Procedural Recommendations
The user is directed to review the “Instructions For Use” for the compatible delivery devices prior to treatment.

6 IRIDEX Cyclo G6™Laser System Operator Manual
66294-EN Rev D
Contraindications
•Any situation where the target tissue cannot be adequately visualized or stabilized.
•Do not treat albino patients who have no pigmentation.
Potential Side Effects or Complications
•As with any surgical procedure, there is the potential risk of infection, inflammation, and post-operative pain.
Specific Warnings and Precautions
It is essential that the surgeon and attending staff be trained in all aspects of the use of this equipment. Surgeons
should obtain detailed instructions for proper use of this laser system before using it to perform any surgical
procedures. For additional Warnings and Cautions, see “Warnings and Cautions” in this chapter. For clinical
information, see “References” at the end of this manual. Proper eye protection must be utilized for the specific
treatment laser wavelength in use (810 nm).
Laser Settings
CAUTION: The following treatment parameters are those reported by physicians using IRIDEX products, or
like products, either in published literature or reported directly to IRIDEX. These treatment
parameters are presented as guidance ultimately it is the physician’s responsibility to determine
safe treatment parameters that will be used on patients on a case by case basis.
The laser energy is recommended to be administered via the probe optical fiber delivery handpiece which is used
intra-ocularly.
Beginning at low power with short duration exposures, the surgeon should note the surgical effect and increase
power, power density, or exposure duration until the desired surgical effect is obtained. The information in the
following tables is intended to provide guidance only for treatment settings, which are not prescriptive for any
condition. The operative needs of each patient should be individually evaluated based on the indication,
treatment location, and on the patient’s medical and wound healing history. If uncertain of expected clinical
response, always start with a conservative setting and increase the setting in small steps.
810 nm Typical Laser Treatment Parameters for Ocular Photocoagulation
810 nm Continuous-Wave*
Application
Delivery Device
Power
(mW)
Exposure
Duration (ms)
Treatment Application
Sites
Total Energy (J)
Transscleral
Cyclophotocoagulation
G-Probe™
1250-1500
3500 –4000
18-20
79-120
Transscleral
Cyclophotocoagulation
G-Probe™
Illuminate
1250-1500
3500 –4000
18-20
79-120
810 nm MicroPulse®**
Application
Delivery Device
Power
(mW)
Duty Cycle
(500 Hz)
Exposure Duration (ms)
Total Energy (J)
Transscleral
Cyclophotocoagulation
MicroPulse® P3
2000-2250
31.3%
50,000-180,000 Superior
50,000-180,000 Inferior
31-126

66294-EN Rev D
Introduction 7
References
*G-PROBE™
1. Gaasterland DE. Diode Laser Cyclophotocoagulation. Glaucoma Today 2009 Mar:35-39.
2. Gaasterland DE, Radcliffe NM, Vold SD, Kammer JA. Reconsidering Transscleral Cyclophotocoagulation.
Supplement to Glaucoma Today 2012 Jan-Feb:1-11
3. Kraus CL, Tychsen L, Lueder GT, Culican SM. Comparison of the Effectiveness and Safety of Transscleral
Cyclophotocoagulation and Endoscopic Cyclophotocoagulation in Pediatric Glaucoma. J Pediatr Ophthalmol
Strabismus 2014;51(2):120-127.
4. Lin SC. Endoscopic and Transscleral Cyclophotocoagulation for the Treatment of Refractory Glaucoma.
J Glaucoma 2008;17:238–247.
5. Olivier MM. Current Options for Cyclophotocoagulation: An overview of transscleral diode photocoagulation
and endocyclophotocoagulation. Glaucoma Today 2012 Mar-Apr:30-34.
6. Schlote T, Derse M, Rassmann K, Nicaeus T, Dietz K, Thiel H. Efficacy and Safety of Contact Transscleral
Diode Laser Cyclophotocoagulation for Advanced Glaucoma. J Glaucoma 2001;10:294-301.
7. Wilensky JT, Kammer J. Long-term Visual Outcome of Transscleral Laser Cyclotherapy in Eyes with
Ambulatory Vision. Ophthalmology 2004;111:1389–1392.
*G-PROBE™ ILLUMINATE: (includes references for G-Probe as well as the two references below)
1. Agrawal P, Martin KR. Ciliary body position variability in glaucoma patients assessed by scleral
transillumination. Eye 2008;22:1499-1503
2. Agrawal P, Dulku S, Nolan W, Sung V. The UK National Cyclodiode Laser Survey. Eye 2010:1-6
**MICROPULSE® P3
1. Radcliffe N, Vold S, Kammer J, Ahmed I, Parekh P, Noecker R, Khatana A. MicroPulse Trans-scleral
Cyclophotocoagulation (mTSCPC) for the Treatment of Glaucoma Using the MicroPulse P3 Device.
AGS, San Diego February 26 -March 1, 2015
2. Aquino MC, Tan AM, Loon SC, Chew PT. Transscleral Micropulse Diode Laser Cyclophotocoagulation as
Effective Adjunctive Treatment prior to Glaucoma Surgery. ARVO 2012 May.
3. Aquino MC, Tan AM, Loon SC, See J, Chew PT. A Randomized Comparative Study of the Safety and Efficacy
of Conventional Versus Micropulse Diode Laser Transscleral Cyclophotocoagulation in Refractory Glaucoma.
ARVO 2011 May.
4. Liu GJ, Mizukawa A, Okisaka S. Mechanism of Intraocular Pressure Decrease after Contact Transscleral
Continuous-Wave Nd:YAG Laser Cyclophotocoagulation. Ophthalmic Res 1994;26:65-79.
5. Schubert HD, Agarwala A. Quantitative CW Nd:YAG Pars Plana Transscleral Photocoagulation in
Postmortem Eyes. Ophthalmic Surgery 1990;21(12):835-39.
6. Aquino MC, Tan AM, Chan YH, Chew PT. Initial Experience with MicroPulse Diode Laser Transscleral
Cyclophotocoagulation for Severe Glaucoma. World Glaucoma Congress 2007 July;P428.
7. Tan AM, Chockalingam M, Aquino MC, Lim ZI, See JL, Chew PT. Micropulse Transscleral Diode Laser
Cyclophotocoagulation in the Treatment of Refractory Glaucoma. Clin Experiment Ophthalmol. 2010
Apr;38(3):266-72
8. Aquino MC, Barton K, Tan AM, Sng C, Li X, Loon SC, Chew PT. Micropulse versus continuous wave trans-
scleral diode cyclophotocoagulation in refractory glaucoma: a randomised exploratory study. Clin Experiment
Ophthalmol May 2014. doi: 10.1111.ceo. 12360 [Epub ahead of print].
9. Kuchar S, Moster M, Waisbourd M. Treatment Outcomes of MicroPulse Trans-scleral Cyclophotocoagulation
in Advanced Glaucoma. Laser Med Sci (2016) 31:393-396.
10. Maslin J, Noecker R, Micropulse Trans-scleral Cyclophotocoagulation for the Treatment of Glaucoma.
Presented at ARVO, May 2-5, 2016.
11. Lin S, Babic K, Masis M, Micropulse transscleral diode laser cyclophotocoagulation: Short term results and
anatomical effects. Presented at AGS 2016, March 3-6, 2016.
12. MaslinJ,ChenP,SinardJ, NoeckerR,Comparisonofacutehistopathologicalchangesinhumancadavereyesafter
MicroPulse and continuous wave transscleral cyclophotocoagulation. Presented at AGS 2016, March 3-6, 2016.
13. Patel K, Dawood S, Rafay H, Patrianakos T, Giovingo M, Results of a Novel Glaucoma Treatment: MicroPulse
Transscleral Cyclophotocoagulation Diode Laser. Presented at ARVO 2016, May 2-5, 2016.

8 IRIDEX Cyclo G6™Laser System Operator Manual
66294-EN Rev D
Warnings and Cautions
DANGER:
Do not remove cover as this may expose persons to hazards of electrical shock and laser radiation.
Refer servicing to qualified laser personnel. There is a risk of explosion if a laser system is used in the
presence of flammable anesthetics.
WARNINGS:
Lasers generate a highly concentrated beam of light that may cause injury if improperly used. To
protect the patient and the operating personnel, the entire laser and the appropriate delivery system
operator manuals should be carefully read and comprehended before operation.
Never look directly into the aiming or treatment beam apertures or the fiber-optic cables that deliver
the laser beams, with or without laser safety eyewear.
Never look directly into the laser light source or at laser light scattered from bright reflective surfaces.
Avoid directing the treatment beam at highly reflective surfaces such as metal instruments.
Ensure that all personnel in the treatment room are wearing the appropriate laser safety eyewear.
Never substitute prescription eyewear for laser safety eyewear.
To avoid the risk of electric shock, this equipment must be connected to a supply mains with
protective earth.
Before connecting or disconnecting the power cord, make sure that the area is clear of water and any
spillage and that hands are dry.
Always disconnect the laser by grasping the plug and not the power cord. Power is shut off by
removing the plug from the electrical main.
Instructions provided, indicate not to position the laser to make it difficult to operate the plug of the
power cord since the plug is used to provide isolation from electrical shock. Do not place the laser in
an area where access to the plug of the power cord is obstructed or prevented.
To avoid the risk of electric shock, this equipment must only be connected to a supply main with
protective earth. EN 60601-1:2006/AC:2010
US federal law restricts this device to sale by or on the order of a healthcare practitioner licensed by
the law of the State in which he/she practices to use or order the use of the device.
Use of controls or adjustments or performing of procedures other than those specified herein may
result in hazardous radiation exposure.
Do not operate the equipment in the presence of flammables or explosives, such as volatile anesthetics,
alcohol, and surgical preparation solutions.
Laser plume may contain viable tissue particulates.
Keep the protective cap over the fiber-optic connector when the delivery device is not in use.

66294-EN Rev D
Introduction 9
IRIDEX Corporation Contact Information
IRIDEX Corporation
1212 Terra Bella Avenue
Mountain View, California 94043-1824 USA
Telephone: [phone]
[phone] (US only)
Fax: [phone]
Technical Support: [phone]
[phone] (US only)
[email protected]
Emergo Europe
Prinsessegracht 20
2514 AP The Hague
The Netherlands
Warranty and Service: Each laser system carries a standard factory warranty. The warranty covers all parts
and labor required to correct problems with materials or workmanship. This warranty
is void if service is attempted by anyone other than certified IRIDEX
service personnel.
WARNING: Use only IRIDEX delivery devices with the IRIDEX laser system. Use of a non-IRIDEX delivery
device may result in unreliable operation or inaccurate delivery of laser power. This Warranty
and Service agreement does not cover any damage or defect caused by the use of non-IRIDEX
devices.
NOTE: This Warranty and Service statement is subject to the Disclaimer of Warranties, Limitation of Remedy,
and Limitation of Liability contained in IRIDEX’s Terms and Conditions.
WEEE Guidance. Contact IRIDEX or your distributor for disposal information.

10 IRIDEX Cyclo G6™Laser System Operator Manual
66294-EN Rev D
2
Setup
Unpacking the System
Make sure you have all components that were ordered. Check components for damage before use.
NOTE: Contact your local IRIDEX Customer Service Representative if there are problems with your order.
Appearance and type of components may vary based on the system ordered.
•Laser •Operator Manual (not shown)
•Power cord (U.S. configuration shown) •Laser warning sign (not shown)
•Keys •Optional accessories (not shown)
•Standard wired footswitch
Laser
Remote Control
(optional)
Wireless
Footswitch
(optional)
Standard Wired
Footswitch
Keys
Power cord

66294-EN Rev D
Setup 11
Choosing a Location
Choose a well-ventilated location within the specified operating range of the console.
Place the laser system on a table or on existing operating room equipment. Allow at least 5 cm (2 in.) of
clearance on each side.
In the US, this equipment must be connected to an electrical supply source at 120V or 240V with a center tap.
To ensure that all local electrical requirements can be met, the system is equipped with a medical grade universal
input power supply three-wire grounding plug. When choosing the location, ensure that a grounding-type AC
outlet is available; it is required for safe operation.
The power cord included in the packaging is appropriate for your location. Always use an approved three-wire
grounding cord set. Do not alter the power inlet. To ensure proper grounding, follow local electrical codes before
installing the system.
CAUTIONS:
Do not defeat the purpose of the grounding pin. This equipment is intended to be electrically grounded.
Contact a licensed electrician if your outlet prevents you from inserting the plug.
Do not position or use the system near open flames.
Connecting the Components
CAUTION: Do not connect two footswitches to the laser console.
NOTES: Refer to the appropriate delivery device manual for specific connection instructions.

12 IRIDEX Cyclo G6™Laser System Operator Manual
66294-EN Rev D
Cyclo G6™ Rear Panel
Footswitch
and Remote
Remote
USB
Interlock Auxiliary
ACPower Expansion Contact
Inlet
Port
Terminals

66294-EN Rev D
Operation 13
3
Operation
Front Panel Controls
CAUTION: When no delivery device is attached to the system, ensure that the illumination and fiber ports
are closed.
Powering the Laser On and Off
•To turn the laser on, turn the key to the On position.
•To turn the laser off, turn the key to the Off position. Remove and store the key to prevent unauthorized use.
NOTE: The key can be removed in the Off position only.
•In an emergency, press the red EMERGENCY STOP button. This immediately disables the console and all laser
related circuits.
Touchscreen
Display
Treat/Standby
Button
Illumination &
Fiber ports
(see caution
below)
Control Knobs (3)
Keyswitch
Emergency
Stop Button

14 IRIDEX Cyclo G6™Laser System Operator Manual
66294-EN Rev D
Treating Patients
BEFORE TREATING A PATIENT:
•Ensure that the eye safety filter (as appropriate) is properly installed.
•Ensure that the laser components and delivery device(s) are properly connected.
•Post the laser warning sign outside the treatment room door.
NOTE: Refer to Chapter 6, “Safety and Compliance” and your delivery device manual(s) for important
information about laser safety eyewear and eye safety filters.
TO TREAT A PATIENT:
1. Turn on the laser.
2. Reset the counter.
3. Set the treatment parameters.
4. Position the patient.
5. If required, select an appropriate contact lens for the treatment.
6. Ensure that all ancillary personnel in the treatment room are wearing the appropriate laser safety eyewear.
7. Select Treat mode.
8. Position the aiming beam on the treatment site.
9. Focus or adjust the delivery device as applicable.
10. Press the footswitch to deliver the treatment beam.
TO CONCLUDE PATIENT TREATMENT:
1. Select Standby mode.
2. Record the number of exposures and any other treatment parameters.
3. Turn off the laser and remove the key.
4. Collect the safety eyewear.
5. Remove the warning sign from the treatment room door.
6. Disconnect the delivery device(s).
7. Dispose of the delivery device, it is single-use.
8. If a contact lens was used, handle the lens according to the manufacturer’s instructions.

66294-EN Rev D
Operation 15
Using the Laser System
System Interface
C
A
A
Touchscreen
Interface
Displays current parameter and functions, and acts as the interface to select screens
or parameters.
B
Control knobs
Used to adjust parameters on the screen.
C
Laser Button
Toggles between laser Ready and Standby modes.
B

16 IRIDEX Cyclo G6™Laser System Operator Manual
66294-EN Rev D
A
B
C
G
Treat Screen
D E
F
H I J K
A
Displays eye safety filter status and delivery device.
B
Go to Options screen.
C
(Optional) Adjust MicroPulse® settings. When MicroPulse is activated, parameters are displayed to the
right of the button (as shown).
D
Go to Presets screen.
E
Reset pulse counter.
F
Indicates laser mode:
•Ready: Laser is ready; will fire when footswitch is pressed.
•Standby: Laser is disengaged.
•Treat: Laser is firing (footswitch pressed).
G
Aiming Beam and Illumination
H
Displays pulse duration. Adjust with control knob.
I
Countdown timer
J
Displays pulse power. Adjust with control knob. Two power parameters, one for CW-Pulse and one for
MicroPulse (if applicable), are maintained.
K
Displays pulse interval. Adjust with control knob.
WARNING: Except during actual treatment, the laser must always be in Standby mode. Maintaining the laser
in Standby mode prevents accidental laser exposure if the footswitch is inadvertently pressed.